Armata Pharmaceuticals (ARMP) Profit After Tax (2013 - 2026)

Armata Pharmaceuticals has disclosed Profit After Tax across 14 years of filings, most recently posting -$115.3 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$115.3 million, down 1666.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$282.6 million (down 66241.31% YoY), and the FY2025 annual result was -$173.8 million, down 818.79% from the prior year.
• Profit After Tax came in at -$115.3 million for Q1 2026 at Armata Pharmaceuticals, up from -$124.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $9.0 million in Q2 2024 to a low of -$124.3 million in Q4 2025.
• The 5-year median for Profit After Tax is -$10.3 million (2022), against an average of -$24.4 million.
• Across the five-year window, Profit After Tax surged 353.34% in 2024 and slumped 4880.69% in 2025, its largest moves.
• Armata Pharmaceuticals' Profit After Tax stood at -$10.3 million in 2022, then tumbled by 92.43% to -$19.8 million in 2023, then surged by 113.1% to $2.6 million in 2024, then plunged by 4880.69% to -$124.3 million in 2025, then grew by 7.2% to -$115.3 million in 2026.
• The last three Profit After Tax figures came in at -$115.3 million (Q1 2026), -$124.3 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.